Philipp Steiner
- Aging top 2%
- Physiology top 2%
- Biotechnology top 1%
- Cancer Research and Treatments 9
- Oncology top 2%
- CAR-T cell therapy research 7
- Cancer-related Molecular Pathways 6
- HER2/EGFR in Cancer Research 3
- Molecular Biology top 5%
- Ubiquitin and proteasome pathways 3
-
- Monoclonal and Polyclonal Antibodies Research 8
-
- Immunotherapy and Immune Responses 3
-
- Virus-based gene therapy research 2
- Co-authors
- Silvia BacchettiRoderick L. BeijersbergenElinor Ng EatonDaniel A. HaberMatthew MeyersonChristopher M. CounterLeif W. EllisenLiuda Ziaugra
- Cited by
- AgingPhysiologyBiotechnology
- Journals
- Cancer Research (8 papers)Molecular Cancer Therapeutics (2 papers)Clinical Infectious Diseases (1 paper)
- Partner nations
- United StatesGermanyJapan
In The Last Decade
Philipp Steiner
33 papers receiving 2.9k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Aging 95
- Physiology 1.3k
- Biotechnology 332
- Oncology 1.0k
- Molecular Biology 1.9k
Countries citing papers authored by Philipp Steiner
This map shows the geographic impact of Philipp Steiner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp Steiner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp Steiner more than expected).
Fields of papers citing papers by Philipp Steiner
This network shows the impact of papers produced by Philipp Steiner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp Steiner. The network helps show where Philipp Steiner may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Philipp Steiner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 14 | |
| 4 | 2021 | 10 | |
| 5 | 2021 | 3 | |
| 6 | 2021 | 4 | |
| 7 | 2021 | 9 | |
| 8 | 2018 | 10 | |
| 9 | 2016 | 27 | |
| 10 | 2009 | 6 | |
| 11 | Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models | 2008 | 2 |
| 12 | 2007 | 184 | |
| 13 | 2007 | 47 | |
| 14 | 2005 | 184 | |
| 15 | 1997 | 146 | |
| 16 | 1996 | 18 | |
| 17 | 1996 | 19 | |
| 18 | 1995 | 206 | |
| 19 | 1993 | 281 | |
| 20 | [The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients]. | 1993 | 2 |
About Philipp Steiner
Philipp Steiner is a scholar working on Biotechnology, Oncology, Space and Planetary Science, Aging and Radiology, Nuclear Medicine and Imaging, having authored 34 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer Research and Treatments (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), CAR-T cell therapy research (7 papers), Cancer-related Molecular Pathways (6 papers), Ubiquitin and proteasome pathways (3 papers), Immunotherapy and Immune Responses (3 papers), HER2/EGFR in Cancer Research (3 papers) and Virus-based gene therapy research (2 papers). The work is most often cited by research in Aging (95 citations), Physiology (1.3k citations), Biotechnology (332 citations), Oncology (1.0k citations) and Molecular Biology (1.9k citations). Philipp Steiner has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Silvia Bacchetti, Roderick L. Beijersbergen, Elinor Ng Eaton, Daniel A. Haber, Matthew Meyerson, Christopher M. Counter, Leif W. Ellisen, Liuda Ziaugra, Michael J. Davidoff and Qingyun Liu. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Clinical Infectious Diseases, Beton- und Stahlbetonbau and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.